Lamivudine 150 mg + Zidovudine 300 mg + Nevirapine 200 mg
This triple-drug antiretroviral formulation combines two nucleoside reverse transcriptase inhibitors with a non-nucleoside reverse transcriptase inhibitor, forming a well-established regimen for the management of HIV-1 infection under nationally and internationally recommended treatment protocols.
Product Details
Therapeutic Class
Nucleoside Reverse Transcriptase Inhibitors (Lamivudine + Zidovudine)
Non-Nucleoside Reverse Transcriptase Inhibitor (Nevirapine)
Indication
Treatment of HIV-1 infection in adults and adolescents as part of combination antiretroviral therapy (ART), in accordance with WHO and NACO recommendations.
Dosage & Administration
To be administered as per recommended dosing schedules or as prescribed by a healthcare professional.
To be used strictly as part of a combination ART regimen.
Storage
Store below 30°C in a dry place, protected from light and moisture.
Disclaimer
Prescription medicine. To be used only under medical supervision and in line with WHO and NACO treatment guidelines.
Pack Size
60 Tablets